(Q38211881)

English

The safety of dipeptidyl peptidase-4 (DPP-4) inhibitors or sodium-glucose cotransporter 2 (SGLT-2) inhibitors added to metformin background therapy in patients with type 2 diabetes mellitus: a systematic review and meta-analysis

scientific article published on May 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

0 references

The safety of dipeptidyl peptidase-4 (DPP-4) inhibitors or sodium-glucose cotransporter 2 (SGLT-2) inhibitors added to metformin background therapy in patients with type 2 diabetes mellitus: a systematic review and meta-analysis (English)

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

type 2 diabetes

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

systematic review

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1

object named as

Paweł Kawalec

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

author name string

Alicja Mikrut

2

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

Sylwia Łopuch

3

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 May 2014

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

Diabetes - Metabolism: Research and Reviews

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

30

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

269-283

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2494

21 January 2018

Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2494

21 January 2018

Association between oral antidiabetic use, adverse events and outcomes in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2494

21 January 2018

Effect of antidiabetic agents added to metformin on glycaemic control, hypoglycaemia and weight change in patients with type 2 diabetes: a network meta-analysis.

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2494

21 January 2018

Sodium-glucose cotransporter inhibition: therapeutic potential for the treatment of type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2494

21 January 2018

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2494

21 January 2018

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2494

21 January 2018

The addition of sitagliptin to ongoing metformin therapy significantly improves glycemic control in Chinese patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2494

21 January 2018

Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2494

21 January 2018

Efficacy and safety of linagliptin 2.5 mg twice daily versus 5 mg once daily in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2494

21 January 2018

The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2494

21 January 2018

Efficacy and safety of saxagliptin added to metformin in Asian people with type 2 diabetes mellitus: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2494

21 January 2018

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2494

21 January 2018

Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2494

21 January 2018

Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2494

21 January 2018

Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin.

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2494

21 January 2018

Efficacy and tolerability of vildagliptin in patients with type 2 diabetes inadequately controlled with metformin monotherapy

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2494

21 January 2018

Efficacy and tolerability of vildagliptin as add-on therapy to metformin in Chinese patients with type 2 diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2494

21 January 2018

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2494

21 January 2018

Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2494

21 January 2018

Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2494

21 January 2018

Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor.

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2494

21 January 2018

Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2494

21 January 2018

Efficacy and safety of alogliptin added to metformin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension study

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2494

21 January 2018

Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2494

21 January 2018

Combination treatment with ipragliflozin and metformin: a randomized, double-blind, placebo-controlled study in patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2494

21 January 2018

Metformin: an old but still the best treatment for type 2 diabetes

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2494

21 January 2018

The clinical efficacy and safety of sodium glucose cotransporter-2 inhibitors in adults with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2494

21 January 2018

Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2494

21 January 2018

Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2494

21 January 2018

Use of dipeptidyl peptidase-4 inhibitors and the reporting of infections: a disproportionality analysis in the World Health Organization VigiBase

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2494

21 January 2018

Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2494

21 January 2018

Rational therapy for diabetes: early recognition of adverse effects and avoidance of disruptive false alarms

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2494

21 January 2018

Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2494

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, on bacteriuria and urinary tract infection in subjects with type 2 diabetes enrolled in a 12-week, phase 2 study

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2494

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor PF-734200 added to metformin in Type 2 diabetes

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2494

7 January 2021

based on heuristic

inferred from DOI database lookup

A Dose-Ranging Study of the DPP-IV Inhibitor PF-734200 Added to Metformin in Subjects With Type 2 Diabetes*

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2494

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/DMRR.2494

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38211881&oldid=2137962932"